IO Biotech, Inc. (NASDAQ:IOBT – Get Free Report) saw a large decline in short interest in April. As of April 15th, there was short interest totalling 61,800 shares, a decline of 9.4% from the March 31st total of 68,200 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average trading volume of 133,900 shares, the short-interest ratio is currently 0.5 days.
Insiders Place Their Bets
In other IO Biotech news, major shareholder Holdings A/S Novo sold 658,809 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $1.50, for a total transaction of $988,213.50. Following the completion of the transaction, the insider now owns 5,088,258 shares in the company, valued at approximately $7,632,387. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 3.50% of the stock is currently owned by company insiders.
Institutional Trading of IO Biotech
Several institutional investors and hedge funds have recently bought and sold shares of the business. Vivo Capital LLC raised its position in IO Biotech by 104.7% in the 3rd quarter. Vivo Capital LLC now owns 6,173,439 shares of the company’s stock valued at $8,705,000 after purchasing an additional 3,157,894 shares during the last quarter. PFM Health Sciences LP raised its position in IO Biotech by 73.0% in the 4th quarter. PFM Health Sciences LP now owns 2,341,107 shares of the company’s stock valued at $4,401,000 after purchasing an additional 987,654 shares during the last quarter. Armistice Capital LLC purchased a new position in IO Biotech during the 3rd quarter worth $3,029,000. Finally, Stonepine Capital Management LLC purchased a new position in IO Biotech during the 3rd quarter worth $2,785,000. Hedge funds and other institutional investors own 54.76% of the company’s stock.
IO Biotech Trading Down 2.0 %
IO Biotech (NASDAQ:IOBT – Get Free Report) last issued its earnings results on Tuesday, March 5th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.04). On average, analysts forecast that IO Biotech will post -1.41 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of IO Biotech in a report on Wednesday, March 6th.
Get Our Latest Analysis on IOBT
IO Biotech Company Profile
IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
Read More
- Five stocks we like better than IO Biotech
- 3 Best Fintech Stocks for a Portfolio Boost
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Hilton Demonstrates Asset Light is Right for Investors
- Insider Buying Explained: What Investors Need to Know
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for IO Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IO Biotech and related companies with MarketBeat.com's FREE daily email newsletter.